## Contents

**EDITORIAL**

1002  Meeting employees where they are: The rise of workplace mental health services  
*Noy G, Shah RN*

**REVIEW**

1004  Does COVID-19 related symptomatology indicate a transdiagnostic neuropsychiatric disorder? - Multidisciplinary implications  
*Goldstein Ferber S, Shoval G, Zalsman G, Weller A*

**ORIGINAL ARTICLE**

**Case Control Study**

1016  Antidepressants combined with psychodrama improve the coping style and cognitive control network in patients with childhood trauma-associated major depressive disorder  

1031  Can the prediction model using regression with optimal scale improve the power to predict the Parkinson’s dementia?  
*Byeon H*

**Observational Study**

*Ilic M, Ilic I*

1061  Peripartum depression and its predictors: A longitudinal observational hospital-based study  
*Hamed SA, Elwasify M, Abdelhafez M, Fawzy M*

1076  Cross-sectional survey following a longitudinal study on mental health and insomnia of people with sporadic COVID-19  
*Li XJ, Guo TZ, Xie Y, Bao YP, Si JY, Li Z, Xiong YT, Li H, Li SX, Lu L, Wang XQ*

1088  Fear of COVID-19 and emotional dysfunction problems: Intrusive, avoidance and hyperarousal stress as key mediators  
*Falcó R, Vidal-Arenas V, Ortet-Walker J, Marzo JC, Piquerás JA, PSICO-RECURSOS COVID-19 Study Group*

**LETTER TO THE EDITOR**

1102  Difference between treatment-resistant schizophrenia and clozapine-resistant schizophrenia  
*Tseng PT, Chen MH, Liang CS*

1105  Genetics of adult attachment and the endogenous opioid system  
*Troisi A*
Contents

1108 Cardiotoxicity of current antipsychotics: Newer antipsychotics or adjunct therapy?
   Liu Z, Zhang ML, Tang XR, Li XQ, Wang J, Li LL

1112 Underlying disease may increase mortality risk in users of atypical antipsychotics
   Li ZP, You YS, Wang JD, He LP
ABOUT COVER
Editorial Board Member of World Journal of Psychiatry, Rajiv Gupta, MD, Director, Professor, Department of Psychiatry, Institute of Mental Health, Rohtak 124001, Haryana, India. rajivguptain2003@yahoo.co.in

AIMS AND SCOPE
The primary aim of World Journal of Psychiatry (WJP, World J Psychiatry) is to provide scholars and readers from various fields of psychiatry with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJP mainly publishes articles reporting research results and findings obtained in the field of psychiatry and covering a wide range of topics including adolescent psychiatry, biological psychiatry, child psychiatry, community psychiatry, ethnopsychology, psychoanalysis, psychosomatic medicine, etc.

INDEXING/ABSTRACTING
The WJP is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJP as 3.500; IF without journal self cites: 3.313; 5-year IF: 7.380; Journal Citation Indicator: 0.62; Ranking: 89 among 155 journals in psychiatry; and Quartile category: Q3.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Yu-Xi Chen; Production Department Director: Xu Guo; Editorial Office Director: Jia-Ping Yan.
LETTER TO THE EDITOR

Genetics of adult attachment and the endogenous opioid system

Alfonso Troisi

Abstract

Since the pioneering work by Panksepp et al, the neurobiological bases of attachment behavior have been closely linked with opioid neurotransmission. Candidate gene studies of adult individuals have shown that variation in the mu-opioid receptor gene (OPRM1) influences attachment behavior. Early maternal care and the A/A genotype of the A118G polymorphism interact in modulating levels of fearful attachment. Compared to their counterparts carrying the A/A genotype, individuals expressing the minor 118G allele show lower levels of avoidant attachment and experience more pleasure in social situations. Brain imaging research has strengthened the biological plausibility of candidate gene studies. The avoidance dimension of attachment correlates negatively with mu-opioid receptor availability in the thalamus and anterior cingulate cortex, as well as the frontal cortex, amygdala, and insula. Overall, findings from human studies combined with those from animal models suggest that research on the genetic bases of attachment should include the endogenous opioid system among the investigated variables.

Key Words: Genetics; Avoidant attachment; Fearful attachment; Endogenous opioids; OPRM1; A118G polymorphism

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Genetic studies of attachment should target the endogenous opioid system. Candidate gene studies of adult individuals have shown that variation in the mu-opioid receptor gene (OPRM1) influences attachment behavior. Early maternal care and the A/A genotype interact in modulating levels of fearful attachment. Compared to their counterparts carrying the A/A genotype, individuals expressing the minor 118G allele show lower levels of avoidant attachment. Brain imaging research has strengthened the biological plausibility of candidate gene studies. The avoidance dimension of attachment correlates negatively with mu-opioid receptor availability in the thalamus and anterior cingulate cortex, as well as the frontal cortex, amygdala, and insula.

Citation: Troisi A. Genetics of adult attachment and the endogenous opioid system. World J Psychiatry 2022; 12(8): 1105-1107
URL: https://www.wjgnet.com/2220-3206/full/v12/i8/1105.htm
DOI: https://dx.doi.org/10.5498/wjp.v12.i8.1105

TO THE EDITOR

I read with interest the narrative review by Erkoreka et al[1] who analyzed the existing literature regarding the implication of candidate genes related to oxytocin, dopaminergic pathways, serotonergic pathways, and brain-derived neurotrophic factor in adult attachment. Yet, the authors failed to discuss the studies that focused on the opioid pathways, which is surprising considering that, since the pioneering work by Panksepp et al[2], the neurobiological bases of attachment behavior have been closely linked with opioid neurotransmission. In this letter, I summarize the findings of the studies that Erkoreka et al[1] failed to report and show why genetic research on attachment should target the endogenous opioid system.

There is evidence that variation in the mu-opioid receptor gene (OPRM1) influences attachment behavior in both healthy volunteers and patients with psychiatric disorders. Troisi et al[3] aimed at ascertaining if the A118G polymorphism of the OPRM1 moderates the impact of early maternal care on fearful attachment in 112 psychiatric patients. Early maternal care and fearful attachment were measured using the Parental Bonding Inventory and the Relationship Questionnaire (RQ), respectively. The pattern emerging from the RQ data was a crossover interaction between genotype and maternal caregiving. Participants expressing the minor 118G allele had similar and relatively high scores on fearful attachment regardless of the quality of maternal care. By contrast, early experience made a major difference for participants carrying the A/A genotype. Those who recalled higher levels of maternal care reported the lowest levels of fearful attachment whereas those who recalled lower levels of maternal care scored highest on fearful attachment. These data fit well with the differential susceptibility model which stipulates that plasticity genes would make some individuals more responsive than others to the negative consequences of adversity and to the benefits of environmental support and enrichment. In a mixed sample (n = 214) of adult healthy volunteers and psychiatric patients, Troisi et al[4] analyzed the association between the A118G polymorphism of the OPRM1 and avoidant attachment as measured by the Attachment Style Questionnaire. The findings showed that, compared to their counterparts carrying the A/A genotype, both healthy volunteers and psychiatric patients expressing the minor 118G allele showed lower levels of avoidant attachment and experienced more pleasure in social situations.

The biological plausibility of the candidate gene studies reported above is strengthened by findings from brain imaging research. Nummenmaa et al[5] scanned 49 healthy subjects using a mu-opioid receptor-specific ligand and measured their attachment avoidance and anxiety with the Experiences in Close Relationships-Revised scale. The avoidance dimension of attachment correlated negatively with mu-opioid receptor availability in the thalamus and anterior cingulate cortex, as well as the frontal cortex, amygdala, and insula. These results confirm that the endogenous opioid system may underlie inter-individual differences in avoidant attachment style in human adults, and that differences in mu-opioid receptor availability are associated with the individuals’ social relationships and psychosocial well-being.

Overall, findings from human studies combined with those from animal models[6] suggest that research on the genetic bases of attachment should include the endogenous opioid system among the investigated variables.

FOOTNOTES

Author contributions: Troisi A wrote the letter.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Italy

ORCID number: Alfonso Troisi 0000-0002-3483-1318.

S-Editor: Ma YJ
L-Editor: Wang TQ
P-Editor: Ma YJ

REFERENCES
